ASCO 2024: CHAARTED-2 in Prostate Cancer

By The Uromigos - Last Updated: July 10, 2024

Dr. Christos Kyriakopoulos describes the outcome of the CHAARTED-2 study, which analyzed cabazitaxel with abiraterone against abiraterone alone for docetaxel-refractory castration-resistant prostate cancer.

Post Tags:Uromigos-ASCO
Advertisement

Related Podcasts

Episode 374: Mechanisms of HIF Resistance
Uromigos-Kidney Cancer
Episode 372: FDA Accelerated Approval Process
Episode 371: TROPiCS-04 Results From ESMO Asia
Uromigos-Bladder Cancer
Episode 370: Artificial Intelligence in Medical Oncology
Episode 369: Paper of the Month With Bishoy Faltas
Uromigos-Bladder Cancer
Advertisement
Advertisement

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Contributors and Partners

    Editorial Policy

    Advertising

    Connect

    eNewsletters

    Calendar

    Contact Us

    Contribute

    Our Network

    MashupMD

    Cancer Nursing Today

    Urban Health Today

    Blood Cancers Today

    DocWire News

    © 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |